Bioengineered Tooth Restoration in a Large Mammal

Posted on March 29, 2017

Researchers at Okayama University report in Scientific Reports successful tooth regeneration in a postnatal large-animal model. The approach used involves the autologous transplantation of bioengineered tooth germ into a canine jawbone; the in vivo artificially created tooth has the structure, composition and physiological characteristics of a natural tooth.

Conventional therapies for restoring the loss of a tooth — due to e.g. caries, gum disease or injury — essentially consist of replacing the tooth with artificial material or an osseointegrated dental implant. Whole-organ regeneration technology is a promising alternative approach: a new tooth is grown from bioengineered tooth germ transplanted into the jawbone. Takuo Kuboki from Okayama University and colleagues have now demonstrated successful functional tooth restoration via the regenerative method for a postnatal large-animal model (a beagle dog).

The researchers first tested whether bioengineered tooth germ does indeed lead to the formation of a proper tooth. They dissected embryonic tooth germ cells and tissues of a dog 55 days prior to birth, and then reconstructed bioengineered tooth germ by means of a technique known as the organ germ method. The germs were then transplanted into mice. In many cases — Kuboki and colleagues were able to identify the necessary conditions — the germ resulted in tooth-crown formation, featuring both the hard and soft tissues present in natural teeth, after several weeks.

The scientists then performed autologous transplantation experiments. Rather than relying on a donor, autologous treatments make use of an organism’s own stem cells (undifferentiated cells that can develop into specialized cells), avoiding immunological rejection. Applying this to their canine model, Kuboki and co-workers extracted deciduous teeth from the jawbone of a 30-day old beagle dog. Tooth germ engineered from the dog’s permanent tooth cell and tissue was then transplanted, after two days of cell culture, into the dog’s mandible, resulting in tooth eruption 180 days later.

Micro-CT analysis showed that the developmental process of the bioengineered tooth’s formation was practically identical to that of a natural tooth, and, by means of scanning electron microscopy and energy-dispersive X-ray spectroscopy, the bioengineered tooth was found to have the same structure and chemical composition of a natural one. Finally, the researchers demonstrated that the response of the regenerated tooth to a mechanical force was consistent with proper physiological functioning of the periodontal ligament (the tissue that connects the crown to the jawbone).

Regarding the future clinical application of the method to humans, the researchers pointed out that immature wisdom tooth germ would be a possible source of stem-cell germs, as it is available in the human postnatal jawbone. However, this would only pertain to younger people — wisdom teeth mineralize after the age of 7; for elderly patients, other stem-cell sources would need to be identified. In any case, quoting Kuboki and colleagues, “this study highlights the feasibility of fully functional tooth restoration by autologous transplantation of bioengineered tooth germ”.

Background 

Tooth structure and Tooth loss Remedies 

Teeth — playing an essential role in the basic oral functions of mastication, swallowing and pronunciation — comprise hard (such as enamel, dentin and cementum) and soft tissue (such as pulp and periodontal ligaments). As a remedy for tooth loss, fixed dental bridges or removable dentures made from artificial materials have been traditionally used, as well as osseointegrated dental implants: artificial teeth that are directly connected to the jawbone, without intervening soft tissue. Driven by recent advances in biomedical understanding and biotechnological engineering, regenerative technologies for the successful replacement of a lost tooth with uncompromised physiological tooth function — such as the one now reported by Kuboki and colleagues — are intensively researched today.

Donor-organ Versus Autologous Transplantation 

The transplantation experiments carried out by the researchers are of the autologous type: a dog’s own tooth germ stem cells were used to regenerate a missing tooth. An autologous transplantation avoids the potential problem of transplant rejection: when an organism receives a donor organ from another, genetically different organism, the former’s immune system may attempt to destroy the transplant. Another complication can be graft-versus-host disease, caused by immune cells of the donated tissue recognizing the host as foreign and starting to attack host cells. It is therefore expected that future whole-tooth restoration in humans will be done by means of autologous transplantation techniques.

Organ Germ Method 

The approach of Kuboki and co-workers involves the bioengineered organ germ method, studied since about a decade ago. The method aims to regenerate ectodermal organs — organs originating from the so-called ectoderm, the outer embryonic layer — such as teeth, hairs and glands, by replicating the organ’s developmental process starting from bioengineered organ germ. In a natural embryo, organ germ arises from the interaction between epithelium (the tissue at the outer layer of a body's surface) and mesenchyme (tissue sitting below the epithelium). Bioengineered organ germ is created by letting epithelial and mesenchymal tissue or cells interact.

 

Smile Source Announces Henry Schein as Elite Vendor

Posted on March 28, 2017

KINGWOOD, Tex., March 10, 2017 – Smile Source announced today that Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care products and services to office-based dental, animal health, and medical practitioners, is now an elite vendor for 490 Smile Source franchise locations across the U.S. 

“At Smile Source, we are always seeking new vendor relationships to provide our members the best possible service, support, and savings. It is with this intent that we are pleased to make this announcement,” said Trevor Maurer, CEO and President of Smile Source. “Henry Schein has a long history of excellence in the dental industry. This, combined with their culture of service and breadth of product offering, supports our growing membership nationwide.”

“We are proud to partner with Smile Source as their strategy closely aligns with our mission statement. Henry Schein focuses on practice care so that our customers can focus on patient care,” said Mackenzie Richter, Director of Sales for Henry Schein Dental.  

Maurer also shared, “Establishing a strong vendor relationship with Henry Schein allows us to better serve our membership across the country and open doors to continued growth. We are excited for a strong future with Henry Schein as an elite vendor for Smile Source.”

About Smile Source

Smile Source, LP is the largest franchise dental organization supporting independent dentists in the United States, with more than 490 supported dental offices located in 35 states. Based in Kingwood, Texas, Smile Source offers franchisee dentists and team members unmatched buying power with premier vendors, extensive continuing education and professional development, collaborative practice management, and strategic marketing support. For more information, www.smilesource.com.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the NASDAQ 100® indexes, Henry Schein employs nearly 19,000 Team Schein Members and serves more than one million customers.

The company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 110,000 branded products and Henry Schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. The company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 33 countries. The company's sales reached a record $10.6 billion in 2015, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com.

 

Two New Directors Elected to Board of Academy of Osseointegration

Posted on March 28, 2017

Arlington Heights, Ill., March 27, 2017 – Drs. Joseph P. Fiorellini and Robert C. Vogel, both longtime members of Academy of Osseointegration (AO), were elected to the board of directors during the annual business meeting held as part of its 2017 Annual Meeting in Orlando, Fla.

Dr. Fiorellini is professor of periodontics at the University of Pennsylvania School of Dental Medicine. In 1990, he received his DMD from the Harvard School of Dental Medicine and in 1993, was awarded the DMSc degree in the field of oral biology and a Certificate in Periodontology.

Dr. Fiorellini has been a member of AO for nearly two decades. He has served on the Predoctoral Education Committee and is Chair of the Academy of Osseointegration/ Academy of Osseointegration Foundation Research Grant Committee. In addition, he serves as an associate editor of the International Journal of Oral and Maxillofacial Implants (IJOMI).

Dr. Fiorellini has published more than 100 clinical manuscripts, reviews or textbook chapters and received awards related to clinical research, including the Academy of Osseointegration Research Award, the American Academy of Periodontology Young Investigators Award, and the European Association for Osseointegration Research Prize. In addition to AO, Dr. Fiorellini is the vice chair of the American Dental Association Commission on Continuing Education Provider Recognition. Dr. Fiorellini maintains a practice limited to periodontology and implant dentistry.

“I am excited to be a part of the premiere multidisciplinary implant organization. AO’s commitment to clinical and scientific excellence is second to none. I fondly remember all that AO has provided in my career. The opportunities when I was just beginning my career from networking to grant support, to now the pleasure of help young clinicians flourish in the organization and profession,” said Joseph Fiorellini, DMD, DMSc.

A native of Long Island, New York, Dr. Vogel graduated from Columbia University Dental School in 1985 and immediately moved to Florida to begin a general practice residency at Jackson Memorial Hospital in Miami. It was there he decided his practice would focus on implant prosthetic treatment, research, and product evaluation. He opened his private practice in Palm Beach Gardens, Fla., working as a team member with several surgical specialists in the community.

An intense interest in implant dentistry has brought him around the world to learn, collaborate, become friends and work with many of the pioneers in the profession. As an AO member early on, he has served on numerous committees, been published in IJOMI and presented at annual meetings. He has furthered his commitment to implant dentistry as an active Fellow of the International Team for Implantology.

“It’s an honor to be part of an organization that has such a significant impact on maintaining the highest level of ethics, science and education in our profession,” said Robert Vogel, DDS.

Aspen Dental’s “Best Grad Gift Ever” Makes it Easier for New Dentists to Get Their Careers Off to the Right Start

Posted on March 28, 2017

March 9, 2017, 2017 (Syracuse, NY) – New dentists joining Aspen Dental –branded practices have a chance to turbocharge their careers thanks to the launch of the “Best Grad Gift Ever.”  

Through the program, all graduating dental students who accept a job at an Aspen Dental practice by April 30, 2017 are invited to participate in the first-ever “New Grad Edition” of Aspen Dental’s industry-leading VIBE Sessions, an exclusive professional development event, and will be entered into a sweepstakes for a new 2017 Ford Mustang Shelby GT350R. 

“In partnership with Aspen Dental practice owners who serve as mentors to new dentists, we’re committed to making it easier for dentists to achieve their dreams,” said Dr. Arwinder Judge, chief clinical officer at Aspen Dental Management, Inc. “We invest millions of dollars annually to support doctor development and mentorship, and this program is just one more way for us to demonstrate our commitment to supporting dentists at every stage of their career journey.” 

To be eligible, fourth-year dental students or dental residents must accept a job at an Aspen Dental practice by the end of April 2017. All who qualify will be invited to participate in the Aspen Dental VIBE Session: New Grad Edition on September 16-17, 2017 in Chicago, IL, where one lucky winner will be awarded a 2017 Ford Mustang Shelby GT350R. 

Over the past three years, the Aspen Dental VIBE Sessions have brought together hundreds of managing clinical directors, associates and dental students, giving them an opportunity to engage with and learn from the best and brightest via professional development, team-building activities and panel discussions with successful, experienced practice owner and partners. The “New Grad Edition” will be geared specifically to new dentists, sharing a roadmap for building a successful, long-term career and providing attendees the opportunity to network with their peers as well as established practice owners.

VIBE Session attendees will also enjoy a unique VIP experience at the Chicagoland Speedway that includes behind-the-scenes access and a chance to get up close and personal with NASCAR Monster Energy Series driver Danica Patrick, who will hand one new Aspen Dental dentist the keys to brand new 2017 Ford Mustang Shelby GT350R.

For more information, visit BestGradGiftEver.com.

*Ford and Ford Mustang are registered trademarks of Ford Motor Company. All rights reserved.

Peer-Reviewed Bone Augmentation Study Reveals Excellent Results for Nobel Biocare Creos Xenoprotect

Posted on March 27, 2017

  • −  Prospective, randomized controlled clinical trial1 to assess the efficacy of creos xenoprotect, a native non-cross-linked collagen dental membrane

  • −  Treatment with creos xenoprotect results in successful bone augmentation of dehiscence defects at implant sites

  • −  81% reduction in defect height observed after six months with creos xenoprotect and is non-inferior to Bio-Gide®

  • −  Study published in peer-reviewed Clinical Oral Implants Research

    Zurich, Switzerland, March 27, 2017

    Results from a randomized controlled clinical trial have confirmed that creos xenoprotect, a resorbable, non-cross-linked collagen dental membrane, facilitates bone gain to support implant placement in dehiscence defects.

    The alveolar ridge may not present with the adequate dimensions required for implant placement. This may be corrected with guided bone regeneration (GBR), which has demonstrated high long-term implant survival rates2. Dr. Bastian Wessing and colleagues, in a multicenter, prospective study, placed implants to support single restorations in 49 patients, with bone augmentation material placed at dehisced implant sites. This material was immobilized with either creos xenoprotect (Nobel Biocare) or the reference membrane, Bio-Gide® (Geistlich). Both patients and evaluators were blinded to the treatment.

    The aim was to assess the clinical efficacy of creos xenoprotect and test its non-inferiority to Bio-Gide®. With creos xenoprotect, the investigators observed an 81% reduction in defect height six months following the augmentation procedure, compared with a 62% reduction with Bio-Gide®, a difference that was not statistically significant. There were also no statistically significant differences in soft tissue health parameters between the two groups. Moreover, there was a trend toward lower membrane exposure rates with creos xenoprotect than Bio-Gide®. This is consistent with a previously published retrospective clinical case series of patients treated with horizontal bone augmentation procedures that reported a low exposure rate for creos xenoprotect.3

    Together, the results show the efficacy of creos xenoprotect in facilitating bone augmentation and non-inferiority to Bio-Gide® (95% confidence interval).

    These highly relevant findings for dental clinicians, recently published in the peer-reviewed Clinical Oral Implants Research, support creos xenoprotect as a scientific-evidence-based choice for their GBR requirements.

    Hans Geiselhöringer, President, Nobel Biocare said: “For clinicians who want to provide care supported by science, these are very significant findings. The excellent results reported in this clinical trial will give clinicians even greater confidence when choosing creos xenoprotect to treat their patients.

    “At Nobel Biocare we take pride in the wealth of clinical research that demonstrates the high quality of our products and solutions. This is just the latest in a growing body of evidence affirming the efficacy of creos xenoprotect. Guided bone and tissue regeneration makes dental implant treatment a real possibility for even more patients. As this study shows, with creos xenoprotect clinicians can treat more patients better.”

    Read the study: http://onlinelibrary.wiley.com/doi/10.1111/clr.12995/abstract

    Get more information about creos xenoprotect, including clinical cases and scientific studies:

    https://www.nobelbiocare.com/international/en/home/products-and-solutions/regenerative-solutions/creos-xenoprotect.html

    References

    1. (1)  Wessing, B.; Urban, I.; Montero, E.; Zechner, W.; Hof, M.; Alandez Chamorro, J.; Alandez Martin, N.; Polizzi, G.; Meloni,

      S.; Sanz, M. Clin Oral Implants Res epub ahead 2016.

    2. (2)  Sanz-Sanchez, I.; Ortiz-Vigon, A.; Sanz-Martin, I.; Figuero, E.; Sanz, M. J Dent Res 2015, 94, S128.

    3. (3)  Wessing, B.; Emmerich, M.; Bozkurt, A. The International journal of periodontics & restorative dentistry 2016, 36, 179. 

Poor Oral Health and Food Scarcity Major Contributors to Malnutrition in Older Adults

Posted on March 24, 2017

UNC School of Medicine researchers led a study to determine risk factors associated with malnutrition among older adults receiving care in the emergency department. The study, published in the Journal of the American Geriatrics Society, suggests that food scarcity and poor oral health are major risk factors for malnutrition that leads an older adult – already at high risk of functional decline, decreased quality of life, and increased mortality – to land in the emergency department.

Tim Platts-Mills, MD, senior author of the study, said, “For patients who don’t have enough food at home, the solution is pretty obvious and likely much less expensive than paying for the medical care that results from malnutrition: there is an existing national system of food assistance programs, such as Meals on Wheels, and we believe we can use the emergency department to link patients in need to those programs.”

“Even though such programs are relatively inexpensive – about $6 per individual per day – many programs are underutilized and under-funded. We need to link patients to these programs and fund these programs,” added Platts-Mills, who is also co-director of the Division of Geriatric Emergency Medicine at the UNC School of Medicine.   

The study included 252 patients age 65 and older seeking treatment in emergency departments in North Carolina, Michigan, and New Jersey. Participants were screened for malnutrition and then asked about the presence of risk factors.

The overall prevalence of malnutrition in the study sample was 12 percent, which is consistent with previous estimates from U.S. emergency departments and about double the prevalence in community-dwelling adults (those who are not hospitalized and do not live in an assisted-living facility). Of the three sites, patients receiving care in the North Carolina emergency department had the highest rate of malnutrition, 15 percent. The researchers note that North Carolina also has one of the highest rates of older adults living below the poverty line (ranked third out of 50 states).  

Of the risk factors studied, poor oral health was found to have the largest impact on malnutrition. More than half of the patients in the study had some dental problems, and patients with dental problems were three times as likely to suffer from malnutrition as those without dental problems. Ten percent of patients experienced food insecurity – the definition of which was based on responses to questions regarding not having enough food, eating fewer meals, and going to bed hungry. Food insecurity was also strongly associated with malnutrition. Other factors associated with malnutrition that may contribute to the problem include social isolation, depression, medication side effects, and limited mobility. 

Collin Burks, a UNC medical student and the study’s lead author, said, “Improving oral health in older adults will be more challenging but also important. Medicare does not cover dental care. Fixing dental problems not only makes it easier for these individuals to eat but also can improve their self-esteem, quality of life, and overall health. We need affordable methods of providing dental care for older adults.”

Platts-Mills’s research group is now developing and testing interventions to link malnourished older patients identified in the emergency department to food assistance programs in the community. 

This research was funded through a research-training grant from the National Institutes of Health.

 

Dental Wings Presents Dental Wings 3D Printers

Posted on March 22, 2017

At the International Dental Show in Cologne, Germany, Dental Wings presented its Dental Wings 3D Printers—developed through a collaboration with RapidShape GmbH and Shera Werkstoff-Technologie GmbH.

Mike Rynerson, CEO of Dental Wings, says that these new products are " ideal solutions for dentists and labs looking to complete their digital suite with fast, robust, and flexible printers and proven dental materials."

The high speed, accuracy, and reliability of the new professional-grade 3D printers are combined with multiple certified materials, enabling dentists and laboratories to cover a wide range of applications, such as models, castable wax patterns, drill guides, temporary crowns and bridges, custom impression trays, and more. Like all Dental Wings products, these printers are open to third-party design software and materials.

To cover customers’ need for accuracy and productivity, Dental Wings 3D printers is available in three models: D20, D30, and D40. The D20 is touted as a compact solution for use in small labs and dental clinics. Dental Wings offers the D30 and D40 models’ power and flexibility to optimize productivity. All offer high-level precision and aesthetic dental products made from certified and bio-compatible materials.

Researchers Close to Identifying Crucial Gene for Human Cleft Lip and Palate

Posted on March 22, 2017

A group of researchers has found that three siblings born with cleft lip and palate share a common gene mutation associated with the birth defect.

The gene intraflagellar transport 88 (IFT88) ensures transportation antennae (cilia) on embryonic cells travel to the right place, enabling the development of cartilage, bone and smooth muscle in the face and skull.

"Finding this birth defect in every single child in a family is like catching lightning in a bottle because it allowed us to pinpoint the gene mutation that is probably responsible," said Yang Chai, senior author of the study and director of the Center for Craniofacial Molecular Biology at the Herman Ostrow School of Dentistry of USC. "Our finding that the gene IFT88 is involved in cleft lip and palate is unlikely to be mere coincidence."

However, because this study involved only three children, Chai said more investigation is needed to find a causal relationship.

The study -- a collaborative effort between the Ostrow School of Dentistry, the Keck School of Medicine of USC, Children's Hospital Los Angeles and the nonprofit Operation Smile -- was published in the journal Human Molecular Genetics in January.

Operation Smile, an international nonprofit that provides free facial surgeries in developing countries, found and provided support to three siblings -- two boys and a girl -- in Mexico who were born with cleft lip and palate. Their mother did not have the congenital disorder, but their father did. Surgeons at CHLA repaired the orofacial abnormality.

In America, cleft lip and palate is the most common birth defect, according to data from the Centers for Disease Control and Prevention. An estimated 7,000 children are born with cleft lip and palate every year.

"Although most people are not familiar with cleft lip and palate, it is a common congenital anomaly that impacts survival, feeding, speech and has long-term implications if not repaired early and correctly," said Pedro Sanchez, a co-author of the study, a medical geneticist at CHLA and an assistant professor of clinical pathology and pediatrics at the Keck School of Medicine. "It occurs in approximately 1 in 1000 live births.

"Understanding the underlying causes of craniofacial disorders can one day lead to an intervention that can reduce the severity of this birth defect, thereby lessening the social, emotional and financial burden that these families face."

Genome Sequencing Locates a Key Gene Mutation

Researchers went through 32,061 unique gene variations to identify IFT88.

"If someone carries this mutation, they may have a higher chance of giving birth to children with cleft lip and palate," said Chai, associate dean of the Ostrow School. "Doctors can provide consultations to these patients before they give birth, so parents can have surgery lined up and seek out proper care for their newborns."

The study of IFT88 may eventually have far-reaching implications. Other congenital diseases tied to a genetic disorder of cilia on embryonic cells include retinal degeneration, hearing defects, polydactyly (extra fingers or toes at birth) and brain malformations.

Animal Model Supports Genome Sequencing Data

Genome-wide association studies usually use the data of hundreds or thousands of patients to identify a gene mutation, yet it is still an association study.

"In our study, however, the animal model and the human mutation match," Chai said. "In the animal model, there is no doubt. We have shown that 100 percent of the mice who have a single mutation in IFT88 have cleft lip and palate."

 

Nobel Biocare Enhances Immediate Solutions for Immediate Patient Needs

Posted on March 21, 2017

Cologne, Germany, March 21, 2017

Nobel Biocare will display a powerful combination of next-level efficiency and quality at the International Dental Show (IDS) 2017 in Cologne, Germany (March 21–25). Visitors to the Nobel Biocare booth at IDS will discover new breakthrough innovations for immediate implant placement and enhanced workflows developed to reduce time-to-teeth for dental implant patients. Each solution benefits from Nobel Biocare’s long-standing experience in research, development and design.

New solutions shaping the future of patient care

Nobel Biocare continues to lead the industry in innovation for the edentulous and soon-to-be edentulous patient. At the forefront is the next generation of the original and proven All-on-4® treatment concept. In Cologne, Nobel Biocare will present the components that keep the All-on-4® treatment at the forefront of edentulous treatment by significantly enhancing workflow efficiency. These include the new Multi-unit Abutment Plus, which offers significant time savings thanks to a snap-fit function that removes the need for screws during the denture try-in process. 

In addition, Nobel Biocare will preview the Trefoil concept at IDS. Trefoil makes a fixed, final, full-arch restoration possible on the day of surgery thanks to a revolutionary prefabricated, passively fitting framework on three implants and a cost effective restorative workflow. A prospective clinical multi-center study with the Trefoil concept is currently underway, and feedback from participating clinicians has been extremely positive. 

More options to protect soft tissue attachment and save chair time

Also on show at IDS are the latest developments for the On1 concept, the most innovative modular solution that connects the surgical and prosthetic workflows. The On1 Base connects to the implant at surgery and stays in place throughout the lifetime of the restoration, leaving the soft tissue undisturbed for optimized healing. The On1 Concept also offers clinicians peace of mind. Only precision-engineered Nobel Biocare components can be used with the On1 Base, removing the risks associated with ill-fitting third-party abutments.

For a restorative clinician, the On1 Base allows for an improved patient experience, as the discomfort previously associated with the recurrent exchange of components such as healing abutments or impression copings can be completely avoided.  The On1 concept is also designed to shorten treatment times. For example, the On1 IOS Healing Cap supports an intraoral scanning approach, which eliminates conventional impression-taking procedures for delivery of the final crown. Currently available for single teeth, at IDS Nobel Biocare will preview an extension of the concept for short-span implant bridges.

Connecting workflows, from diagnostics to final restorations

In Cologne Nobel Biocare will also launch a new time-saving CAD/CAM-based protocol that enables clinicians to receive a screw-retained TempShell provisional restoration from a dental laboratory in time for placement on the day of implant surgery.

Visitors will be among the first to see the new SmartSetup software feature that dramatically reduces the time it takes clinicians to create a prosthetic-driven treatment plan. This plan can then be used by the dental laboratory for the fully digital design of the cement-free TempShell provisional restoration. Incorporating several of Nobel Biocare’s leading digital technologies, the updated workflow has been developed not only to shorten time-to-teeth, but to increase both treatment efficiency and acceptance as well as further improve collaboration between dental professionals.

Partnership with KaVo sets new standard in treatment efficiency

At IDS Nobel Biocare and KaVo will unveil a partnership to revolutionize the way dental professionals connect with patients and each other. These two leading dental innovators will present new equipment and software solutions that mark the next level of connectivity between treatment steps.

Whether on Mac® or PC, the new DTX Studio diagnostic software, launching in fall 2017, will serve as a digital hub connecting the latest Nobel Biocare and KaVo solutions for patient data digitization, diagnosis, planning, surgery and restoration. DTX Studio is also set to offer easy access to industry-leading implants and restorative options. By providing true, seamless links between every aspect of a dental professional’s daily work, this smart solution aims to set a new standard in treatment efficiency and patient care. For further information, a separate, dedicated press release for DTX Studio is available.

Predictable quality and fast results

IDS sees the next significant step in restorative innovation with the launch of NobelProcera precision-milled implant bridges in high-translucency multilayered zirconia. With the angulated screw channel (ASC) innovation and completely cement-free adapters, this new NobelProcera option offers a fast, predictable and cost-efficient solution for both dental laboratory and clinic.

The ASC option, combined with the pick-up functionality of the unique Omnigrip tooling, revolutionizes screw-retained restorations. It makes it possible to reposition the screw access hole in cases where it would otherwise be on the facial or incisal edge, or when occlusal space is limited, while also improving retrievability and reducing the risk of residual cement.

The NobelProcera launches do not stop there, with precision-milled bridges in the same high-translucency multilayered full-contour zirconia also being unveiled at IDS. Following the recent introduction of the NobelProcera Crown in the same material, this launch harmonizes NobelProcera’s offering. This new range efficiently combines high-strength with esthetics and a time-saving workflow, as the dental technician need only apply subtle staining, if desired, before polishing and glazing.

Hans Geiselhöringer, President, Nobel Biocare said: “At Nobel Biocare we do not believe innovation should stop once a product hits the market. This pursuit of the highest possible quality of care sees us innovating on all fronts to further shorten time-to-teeth for dental implant patients and help ensure long-term treatment success. From the enhancement of the original and proven All-on-4® treatment concept to breakthrough advances in clinical and digital workflows that dramatically reduce treatment times, each solution we present at IDS exemplifies the dedication to continuous improvement and the high quality that Nobel Biocare stands for.

“Quality goes beyond materials. It’s also the supporting clinical evidence, the testing that proves efficacy, and the precision that allows our components to function in harmony as one predictable system. This combination, backed by Nobel Biocare’s unrivaled experience, enables dental professionals to confidently offer the high-quality care their patients deserve.”

The Nobel Biocare booth at IDS is situated in Hall 10.1, H20/J29.

For more information about Nobel Biocare products and solutions visit nobelbiocare.com.

Disclaimer: Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare representative for current product assortment and availability.

 

 

Nobel Biocare and KaVo Kerr unveil DTX Studio™: a single digital platform for all aspects of dental treatment

Posted on March 21, 2017

Cologne, Germany, March 21, 2017

In a joint announcement at the International Dental Show (IDS) in Cologne, Germany, Nobel Biocare and KaVo Kerr will unveil DTX Studio, a single digital platform connecting diagnostics and treatment for dental patients. 

Due to launch in fall 2017, these two leading dental innovators developed DTX Studio to revolutionize connectivity across the entire treatment team. Clinicians, radiologists, operators, assistants, hygienists and dental technicians are all set to benefit from this single software solution. DTX Studio will be accessible from multiple rooms in a dental practice on both Mac® and Windows®.

DTX Studio will be a modular solution, meaning users can select the diagnosis, design and treatment planning modules they need depending on their role and experience level. 

An open system, DTX Studio will connect to KaVo imaging devices, but will also allow import of images from any X-ray device, intraoral scanner or desktop scanner. A diagnostics module will offer a clear, clean interface with multiple work spaces to assist with accurate diagnosis. Tooth-position-based navigation will help the user to structure their findings. 

The DTX Studio implant module* will facilitate the visualization of critical information for precise implant planning according to the desired prosthetic outcome. Tools for enhanced collaboration with the dental technician will make it simple for the clinician to offer patients a CAD/CAM provisional restoration on the day of surgery.

For dental laboratories, the design module combines powerful CAD tools with an intuitive interface. It will enable the quick and easy design of the desired restoration, whether tooth- or implant based. The current NobelDesign software will transition to become part of DTX Studio. 

DTX Studio will also make it simple for dental professionals to connect with their preferred production source. Options will include local production of models and provisional restorations with 3D printing and in-lab milling, with prosthetic frameworks, full-contour restorations and surgical templates available from a Nobel Biocare centralized production center. 

Dr. Pascal Kunz, Vice President Product Management Digital Dentistry, said: “By harnessing the combined expertise of Nobel Biocare and KaVo Kerr – two leading players within Danaher’s Dental Platform – DTX Studio will establish a new benchmark for connectivity in dentistry. Many dental companies claim to offer open, fully integrated workflows, but DTX Studio sets a new standard by truly connecting the various aspects of a modern dental professional’s daily work. While enhancing processes and access to high-quality products it also offers new possibilities and links to new technologies. It will make life easier and more efficient for the entire treatment team and, most importantly, support an enhanced treatment outcome for the patient.” 

 

For more information about DTX Studio visit DTXStudio.com or visit the KaVo Kerr and Nobel Biocare booth at IDS in Hall 10.1, H20/J29.

 

© 2017 AEGIS Communications | Privacy Policy